The final of the 11th Tsinghua University President's Innovation Challenge was held on June 15th, 2024 at Jianhua Building. 168 participating teams went through preliminary selection and semi-finals, and 16 teams stood out and advanced to the finals. After four hours of intense competition, the Migrasome Therapeutics team won the first prize.

Guests and judges attending this event include YANG Bin, Vice President of Tsinghua University, HE Ping, Vice Dean of Tsinghua University School of Economics and Management, HU Chuxiong, Deputy Provost of Tsinghua University, LI Bing, Vice Dean of Office of Technology Transfer of Tsinghua University, YU Cangbi, Director of the Innovation & Entrepreneurship Education Alliance of China, HUANG Feng, Deputy Secretary of CCYL Tsinghua University Committee, YUAN Jianxiong, Secretary General of the Tsinghua Alumni Triple Creation (Entrepreneurship, Innovation, and Creativity) Contest, GUO Meiling, Founder of the Meiling Foundation, LIU Yi, Chairman of Andon Health, SUN Ying, General Manager of the Strategic Development Department of Huatai Securities and Chairman of Huatai Innovation, LI Zhen, General Manager of Zhuhai Huaming Capital, and ZHANG Jinsheng, Vice President of TusHoldings and Chairman of TusStar, WANG Biao, General Manager of Huakong Technology Transfer Co., Ltd., XIN Wang, Managing Director of Gaorong Ventures, LI Zhu and founding partner of InnoAngel Fund and Vice Chairman and President of Beijing Frontier International AI Research Institute, Zhou Hongyi, Founder, Chairman and CEO of 360 Total Security, ZHANG Han, Partner of Sequoia Capital, Huayang, Vice President of Northern Light Venture Capital, ZHANG Yuanjie, Managing Partner of Wise Road Capital, WANG Qiuhu, Partner of Xiangtai Investment, MA Rui, Partner of Frees Fund, ZHANG Ke, Founder of Blake Capital, WANG Xuehui, Executive Director of Tsinghua Alumni Fund, and MA Lin, Partner of SEE Fund.

Group photo

In his speech, HE Ping stated that the President's Innovation Challenge is a brand contest of Tsinghua University, which plays an important role in the innovation and entrepreneurship education system. Many participating teams have gradually grown into industry benchmarks, leading technological progress, and achieving a dual enhancement of personal value and social contribution. The 168 projects participating in this year's contest have mainly focused on "hard technology". The entrepreneurial direction accurately matches the pulse of the times, closely follows the forefront trends of technology and social progress, and demonstrates foresight and sensitivity to the times.

HE Ping delivers a speech.

During the final, 16 teams displayed their strengths and delivered their presentations on the project concept, achievements, and innovation through texts, pictures, and videos.

Team presentations

The defense session was full of highlights. Judges asked questions from various aspects such as project innovation, core advanftages, business models, and market research, and provided constructive suggestions.

Judges

LI Zhu commented that the quality of this year's finals is higher than that of previous years, and biotech related projects fully demonstrate the originality of Tsinghua University. AI related projects are also quite innovative, and especially during the time when their applications have not yet received widespread attention, it is hoped that more disruptive transformative applications in the field of AI could be explored.

LI Zhu makes comments.

The winner of the "Meiling" First Prize, the "Migrasome Therapeutics," has pioneered the development of an engineered migrasome system with a complete quality control process to ensure high-quality production. It has advantages such as targeted delivery, diverse drug loading types, and reasonable production costs. DAI Chen, the R&D director, said that participating in this contest has inspired their innovative thinking and allowed them to see the infinite possibilities of technological innovation. In the future, the team will double its efforts to quickly apply the original biological discovery of "migrasome" to clinical practice, bringing good news to more patients.

First prize winner: Migrasome Therapeutics